LYRA Lyra Therapeutics, Inc.

Nasdaq lyratherapeutics.com


$ 7.71 $ 0.15 (2.04 %)    

Wednesday, 15-Oct-2025 15:59:22 EDT
QQQ $ 603.01 $ 4.22 (0.71 %)
DIA $ 463.35 $ 0.00 (0 %)
SPY $ 665.54 $ 2.94 (0.44 %)
TLT $ 90.75 $ -0.20 (-0.22 %)
GLD $ 387.51 $ 6.60 (1.73 %)
$ 7.52
$ 7.10
$ 7.05 x 100
$ 8.05 x 1,000
$ 7.05 - $ 7.80
$ 3.81 - $ 37.50
65,469
na
12.37M
$ 1.32
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 04-30-2024 03-31-2024 10-Q
7 03-22-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-09-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-09-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-28-2020 03-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lyra-therapeutics-outlines-clinical-plan-for-lyr-210-following-fda-meeting-and-announces-enlighten-2-late-breaking-oral-presentation

Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results high...

 upstreams-new-sinus-treatment-cuts-need-for-surgery-early-trial-finds

Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, conges...

 hc-wainwright--co-reiterates-neutral-on-lyra-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Neutral and maintains $16...

 lyra-therapeutics-q2-eps-551-beats-602-estimate-sales-183000k-beat-171250k-estimate

Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(5.51) per share which beat the analyst consensus estimate of $(6...

 lyra-therapeutics-terminates-executive-chairman-harlan-waksal--maria-palasis-appointed-chair-of-lyra-board

-SEC Filing

 hc-wainwright--co-maintains-neutral-on-lyra-therapeutics-raises-price-target-to-16

HC Wainwright & Co. analyst Matthew Caufield maintains Lyra Therapeutics (NASDAQ:LYRA) with a Neutral and raises the pri...

 us-stocks-likely-to-open-lower-expert-highlights-technical-analysis-showing-sp-500s-recovery-is-real-and-not-a-bull-trap-or-bear-market-rally

U.S. stock futures fell on Tuesday after a higher close on Monday. Futures of major benchmark indices declined in premarket.

 applied-digital-corp-meta-platforms-alphabet-lyra-therapeutics-tesla-why-these-5-stocks-are-on-investors-radars-today

U.S. stocks closed higher on Monday, with the Dow Jones Industrial Average inching up 0.08% to 42,305.48, the S&P 500 advan...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION